TYTO CARE LTD

Protalix BioTherapeutics Appoints Gilad Mamlok as New CFO to Drive Growth Strategy

- Protalix BioTherapeutics has appointed Gilad Mamlok as Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. - Mamlok brings three decades of experience in healthcare and technology companies, including roles at TytoCare, Sol-Gel Technologies, and Given Imaging. - The appointment comes as Protalix continues to advance its pipeline of plant cell-based therapeutic proteins, including approved products Elfabrio and taliglucerase alfa. - The company's proprietary ProCellEx platform represents the first FDA-approved protein production system using plant cell-based suspension expression technology.